Novo Nordisk’s Rally Faces a Test: Medicare Tailwinds Meets Analyst Caution and a Billion-Dollar Parent Payday
Published on 07/06/2026 at 19:32 | Redaktion boerse-global.de
The past month has brought some much-needed relief to Novo Nordisk shareholders. After shedding nearly a third of its value from the July 2025 record high, the stock has rebounded 15.39% over the last 30 days to trade at €43.01. That still leaves the Danish pharmaceutical giant down 3.75% on the year and 27.38% below where it stood twelve months ago, but the recovery from the March 52-week low of €30.25 now stands at 42.17%. The question on everyone’s lips: is this the start of a sustained turnaround or just a dead-cat bounce?
Behind the rally sits a powerful catalyst. The new Medicare Bridge Program, which took effect on 1 July, allows eligible US seniors to access Wegovy for a monthly copay of $50, with the scheme running through to the end of 2027. For the first time, obesity treatment is reimbursed under Medicare, unlocking a massive patient pool. Analysts expect the expanded access to drive additional billions in revenue, though the benefit is not exclusive — rival Eli Lilly enjoys identical terms for its tirzepatide products, which already command over 60% of the US obesity market.
Adding to the positive news flow, the parent company Novo Holdings has exited a portfolio company in style. Myricx Bio, a research-stage biotech backed by the Novo Nordisk parent, has been sold to Novartis for up to $1.5 billion. Of that, $1.1 billion is upfront cash — a clear signal that the group’s venture arm continues to identify and monetise promising platforms. While the sale does not flow directly to Novo Nordisk’s bottom line, it underscores the financial muscle and deal-making savvy of the broader Novo ecosystem.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The bullish thesis extends beyond Medicare. The oral version of Wegovy has been gaining traction since its January 2026 US launch. By early June, prescriptions had already topped three million. Seeking Alpha recently reiterated a Buy rating with a $75 price target, citing upgraded 2026 guidance and stronger-than-expected GLP-1 sales. Management is also pointing to international growth as a further tailwind.
Yet not everyone is convinced. Jefferies analyst Michael Leuchten maintained a Hold rating with a target of DKK 285, a stance echoed by J.P. Morgan’s Richard Vosser. Nordea Markets upgraded the stock to Buy on 19 June, but the split among analysts is stark. The sceptics point to Novo Nordisk’s own forecast from February, which projects a 5% to 13% decline in adjusted revenue and operating profit for the 2026 financial year. That conservative outlook continues to weigh on sentiment, as does Eli Lilly’s dominant grip on the US obesity market.
The technical picture adds another layer of complexity. The stock currently sits 10.61% above its 50-day moving average of €38.88 and 5.51% above the 200-day average of €40.76. In Copenhagen, the share price broke above the 200-day line to close at DKK 326.90. However, the 14-day relative strength index of 67 points to an overbought condition in the near term, while the annualised 30-day volatility of 31.52% suggests further choppy trading lies ahead.
Investors will have to wait for hard data to break the deadlock. The next quarterly results are due on 5 August, followed by a capital markets day on 21 September where management is expected to unveil new financial targets. Until then, the stock looks caught between the optimism of Medicare-related revenue potential and the caution prompted by its own cautious guidance — a tug-of-war that is unlikely to resolve quietly.
Ad
Novo Nordisk Stock: New Analysis - 6 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
